PT-141 common uses, half-life, side effects and more

PT-141 is bremelanotide. It is a synthetic peptide taken to raise sexual desire and arousal. The FDA approved an injectable form for premenopausal women with hypoactive sexual desire disorder. That is persistent low sexual desire that causes distress and is not explained by another illness, a relationship problem, or a medication. The approved product is prescription only and is not approved for men, for postmenopausal women, or for boosting sexual performance. Men's clinics and peptide users still take it off label for libido, arousal, and erectile dysfunction. Gray market powders and nasal sprays sold as PT-141 come from a different supply chain than the approved autoinjector.

• Approved treatment for low sexual desire in premenopausal women
• Off label libido and arousal support in men and women
• Erectile dysfunction that did not respond to standard PDE5 inhibitor pills
• Dosing on demand before sexual activity
• Research chemical powders and nasal sprays sold as PT-141

As needed before sexual activity

The approved dose is 1.75 mg injected under the skin of the abdomen or thigh at least 45 minutes before sex. The label allows no more than one dose in 24 hours and no more than 8 doses in a month. Off label use in men runs about 0.5 to 2 mg under the skin before sex. Many start near 0.5 to 1 mg to gauge nausea and settle around 1 to 2 mg. Historical nasal studies used far larger amounts of roughly 7.5 to 20 mg. No nasal product was ever approved. Nasal doses must never be matched to an injection.

• The approved autoinjector delivers a fixed 1.75 mg dose that cannot be changed
• Nasal development was halted over rising blood pressure and uneven absorption
• Approved use is meant to stop after 8 weeks when desire has not improved

Terminal plasma half-life is about 2.7 hours after the approved subcutaneous dose. The label gives a range of 1.9 to 4.0 hours. The discontinued nasal formulation cleared a little faster at about 1.85 to 2.09 hours.

The approved autoinjector is stored at or below 25 degrees Celsius, kept out of light, and not frozen.

• Nausea hit 40% of patients in trials and was the top reason for stopping
• Flushing, headache, vomiting, cough, fatigue, tingling, dizziness, or nasal congestion can occur
• Injection site pain, redness, bruising, itching, bleeding, numbness, or altered sensation can occur
• Blood pressure rises and heart rate falls for a few hours after each dose
• Focal darkening of the face, gums, or breasts can occur and may not fully resolve
• Gray market products can expose users to wrong dose, wrong identity, sterility failure, or endotoxin contamination

Bremelanotide activates the melanocortin receptors. The body uses that receptor family for pigment, appetite, and sexual function. It is nonselective and binds several of these receptors. The approved label ranks its potency as MC1R, MC4R, MC3R, MC5R, and MC2R. It treats the MC1R and MC4R actions as the most relevant at approved doses. MC4R signaling in the brain is the leading proposed route to greater sexual desire and arousal. The exact way it helps low desire is officially unknown. Its work on brain circuits sets it apart from erectile dysfunction pills that act on blood vessels in the penis. MC1R activation on pigment cells explains the skin and gum darkening some users see.

Evidence is strongest for the approved use in premenopausal women. Two 24-week randomized placebo-controlled trials tested 1.75 mg under the skin in about 1247 women. Both raised desire scores and lowered distress scores by small but statistically significant amounts. Neither increased the number of satisfying sexual events over placebo. A 52-week extension followed longer use but had no control group. Evidence in men is older, smaller, and weaker. Two 2004 studies measured erections after 4 mg and 6 mg injections in men who responded poorly to sildenafil. The one large male trial carries a published expression of concern tied to a wider data-integrity case. Off label male use rests on clinic protocols and community practice rather than on trials.

• Uncontrolled high blood pressure or known heart disease is a contraindication because each dose briefly raises blood pressure
• Taking more than one dose in 24 hours or more than 8 doses a month can raise blood pressure further
• Skin and gum darkening can be permanent and reached 38% with 8 days of daily dosing versus about 1% at the monthly limit
• Pregnancy is not recommended and reliable contraception is advised during use
• Oral naltrexone should be avoided because bremelanotide can lower how much of it the body absorbs
• Bremelanotide slows stomach emptying and can delay or weaken oral medicines that need reliable absorption